{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:21:24Z","timestamp":1789129284870,"version":"build-2803163510"},"reference-count":34,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"unspecified","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S1092852924002360_sec1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antidepressants are commonly prescribed for mood disorders. Epidemiological studies suggest antidepressant use may be associated with cataracts and glaucoma. We aim to investigate the association between antidepressants and cataracts and glaucoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1092852924002360_sec2\" sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data was collected from the United States Food and Drug Administration Adverse Event Reporting System. Reporting odds ratio (ROR) and Bayesian information components (IC\n                      <jats:sub>025<\/jats:sub>\n                      ) were calculated for antidepressants (ie, selective serotonin reuptake inhibitors [SSRIs], selective norepinephrine reuptake inhibitors [SNRIs], serotonin-norepinephrine-dopamine reuptake inhibitors, serotonin modulators and stimulators, serotonin antagonists and reuptake inhibitors [SARIs], norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, tricyclic antidepressants [TCAs], tetracyclic antidepressants [TeCAs], and monoamine oxidase inhibitors [MAOIs]). The reference agent was acetaminophen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1092852924002360_sec3\" sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TeCAs and MAOIs were significantly associated with a decreased risk of cataracts (ROR = 0.11-0.65 and 0.16-0.69, respectively). TCAs, brexanolone, esketamine, and opipramol reported an increased cataract risk (ROR = 1.31-12.81). For glaucoma, SSRIs, SNRIs, SARIs, TCAs, MAOIs, and other investigated antidepressants reported significant RORs ranging from 1.034 to 21.17. There was a nonsignificant association of angle closure glaucoma (ACG) and open angle glaucoma (OAG) with the investigated antidepressants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1092852924002360_sec4\">\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>For adverse event cases, multiple suspected product names are listed, and as cases are not routinely verified, there may be a possibility of duplicate reports and causality cannot be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1092852924002360_sec5\" sec-type=\"conclusions\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most of the investigated antidepressants were associated with a lower risk of cataract reporting. TCAs, brexanolone, esketamine, and opipramol were associated with greater odds of cataract. For most antidepressants, there was an insignificant increase in reports of ACG and OAG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/s1092852924002360","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T01:04:07Z","timestamp":1736125447000},"page":"682-696","source":"Crossref","is-referenced-by-count":8,"title":["Association of antidepressants with cataracts and glaucoma: a disproportionality analysis using the reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS) pharmacovigilance database"],"prefix":"10.1017","volume":"29","author":[{"given":"Gia Han","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela T.H.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3968-3297","authenticated-orcid":false,"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maj","family":"Vinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-2676","authenticated-orcid":false,"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"S1092852924002360_r7","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000245"},{"key":"S1092852924002360_r31","doi-asserted-by":"publisher","DOI":"10.2147\/OPTO.S355091"},{"key":"S1092852924002360_r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2019.04.010"},{"key":"S1092852924002360_r12","first-page":"887","article-title":"Glaucoma is the second leading cause of blindness globally","volume":"82","author":"Kingman","year":"2004","journal-title":"Bull World Health Organ."},{"key":"S1092852924002360_r15","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418080-00001"},{"key":"S1092852924002360_r6","unstructured":"6. United States Food and Drug Administration (FDA). Depression Medicines, From the FDA Office of Women\u2019s Health, n.d. [cited 2024 March 7]. https:\/\/www.fda.gov\/consumers\/womens-health-topics\/depression-medicines. Accessed 07 March, 2024."},{"key":"S1092852924002360_r2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001547"},{"key":"S1092852924002360_r21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04037.x"},{"key":"S1092852924002360_r28","first-page":"69","article-title":"Family history and risk of primary open angle glaucoma","volume":"112","author":"Tielsch","year":"1994","journal-title":"Baltimore Eye Survey Arch Ophthalmol."},{"key":"S1092852924002360_r3","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21120"},{"key":"S1092852924002360_r4","doi-asserted-by":"publisher","DOI":"10.2174\/157015908787386104"},{"key":"S1092852924002360_r13","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2018.1506036"},{"key":"S1092852924002360_r1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01227-8"},{"key":"S1092852924002360_r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.07.049"},{"key":"S1092852924002360_r33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173005"},{"key":"S1092852924002360_r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.11.042"},{"key":"S1092852924002360_r22","volume-title":"Principles of Biostatistics","author":"Pagano","year":"2018"},{"key":"S1092852924002360_r11","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000002248"},{"key":"S1092852924002360_r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108662"},{"key":"S1092852924002360_r19","first-page":"219","article-title":"Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration properties","volume":"7","author":"Mohamed","year":"2013","journal-title":"Clin Opthamol."},{"key":"S1092852924002360_r23","unstructured":"23. Deeks, JJ , Higgins, JPT . Statistical Algorithms in Review Manager 5, 2010 [cited 2024 March 7]. https:\/\/training.cochrane.org\/"},{"key":"S1092852924002360_r27","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.097295"},{"key":"S1092852924002360_r34","doi-asserted-by":"publisher","DOI":"10.2174\/157015908787386104"},{"key":"S1092852924002360_r20","volume-title":"Odds Ratio","author":"Tenny","year":"2023"},{"key":"S1092852924002360_r24","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15581"},{"key":"S1092852924002360_r25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132947"},{"key":"S1092852924002360_r18","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2021.0020"},{"key":"S1092852924002360_r8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85380-6"},{"key":"S1092852924002360_r26","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0699-0"},{"key":"S1092852924002360_r5","first-page":"37","article-title":"Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison","volume":"11","author":"Sansone","year":"2014","journal-title":"Innov Clin Neurosci."},{"key":"S1092852924002360_r10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192"},{"key":"S1092852924002360_r14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173005"},{"key":"S1092852924002360_r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.03.006"},{"key":"S1092852924002360_r30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.947659"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852924002360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:39:38Z","timestamp":1739954378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852924002360\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1092852924002360"],"URL":"https:\/\/doi.org\/10.1017\/s1092852924002360","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}